A phase 2 trial to evaluate safety and immunogenicity of a next-generation COVID-19 vaccine delivered by inhaled aerosol to humans

一项 2 期试验，旨在评估通过吸入气雾剂向人类输送的下一代 COVID-19 疫苗的安全性和免疫原性

• 批准号: 466312
• 负责人: Smaill Fiona M
• 金额: $ 602.2万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-07-01 至 2025-07-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=466312&lang=en
• 关键词: Adenoviral-Vectored; Antibody & T Cell Immunity; Clinical Trial; Covid-19; Inhaled Aerosol; Mucosal Immunization; Next-Generation Vaccine; Respiratory Mucosal Immunity; Sars-Cov2; Trained Innate Immunity

Despite the benefit of current COVID vaccines in preventing severe disease and death, these vaccines are relatively poor at preventing infection with new variants like Omicron and work less well in the elderly and people with weak immune systems. There is

尽管目前的COVID疫苗在预防严重疾病和死亡方面有好处，但这些疫苗在预防Omicron等新变种感染方面相对较差，并且在老年人和免疫系统较弱的人中效果较差。有